US EditionPublished • loading... • Updated
Published in The Lancet: Nipocalimab significantly decreased Sjögren's disease (SjD) activity and severity through substantial reduction in Sjögren's-related autoantibodies
- Nipocalimab met its primary endpoint by showing statistically significant improvement in the ClinESSDAI score at Week 24 compared to placebo, as detailed in the Phase 2 DAHLIAS study.
- Patients receiving nipocalimab experienced greater improvements in critical Sjögren's disease symptoms, including dryness, pain, and fatigue, as reported in the study findings.
- Nipocalimab demonstrated a tolerable safety profile with no new safety signals observed during the 24-week treatment period.
- There is a significant unmet need for effective treatments for Sjögren's disease, as 9 out of 10 patients are women experiencing persistent symptoms with no approved therapies available.
Insights by Ground AI
62 Articles
62 Articles
Bennington Banner+61 Reposted by 61 other sources
Published in The Lancet: Nipocalimab significantly decreased Sjögren's disease (SjD) activity and severity through substantial reduction in Sjögren's-related autoantibodies
Nipocalimab, a first-in-class FcRn blocker being investigated for SjD, met its primary endpoint in the Phase 2 DAHLIAS study with statistically significant improvement in ClinESSDAI score , which is based on 11 key systemic disease domains, at Week 24 versus…
Coverage Details
Total News Sources62
Leaning Left8Leaning Right6Center24Last UpdatedBias Distribution63% Center
Bias Distribution
- 63% of the sources are Center
63% Center
L 21%
C 63%
R 16%
Factuality
To view factuality data please Upgrade to Premium
